Round Up

Five things for pharma marketers to know: Tuesday, November 28, 2017

Five things for pharma marketers to know: Tuesday, November 28, 2017

By

FDA plans new guidance to bring complex generics to market more quickly; BioMarin sells priority review voucher for $125 million; Takeda expects Zika clinical trial results next year

Five things for pharma marketers to know: Wednesday, November 22, 2017

Five things for pharma marketers to know: Wednesday, November 22, 2017

WebMD reportedly lays off 10% of workforce; Roche blocks Herceptin biosimilar with patent suit; insurers cover Collegium's Xtampza over Purdue's OxyContin

Five things for pharma marketers to know: Tuesday, November 21, 2017

Five things for pharma marketers to know: Tuesday, November 21, 2017

By

J&J to hold meeting on maintaining Remicade market share; Acorda ends development of Parkinson's drug; Darzalex notches positive first-line results

Five things for pharma marketers to know: Friday, November 17, 2017

Five things for pharma marketers to know: Friday, November 17, 2017

By

FDA approves Genentech's hemophilia drug; former Insys CEO pleads not guilty to bribery charges; federal jury rules in favor of Endo in Testim lawsuit

Five things for pharma marketers to know: Wednesday, November 15, 2017

Five things for pharma marketers to know: Wednesday, November 15, 2017

By

FDA approves AstraZeneca asthma drug; Senate tax reform bill would repeal Obamacare mandate; J&J drops Remicade biosimilar lawsuit

Five things for pharma marketers to know: Wednesday, November 8, 2017

Five things for pharma marketers to know: Wednesday, November 8, 2017

By

FDA to change Risk Evaluation Mitigation Strategies to prevent delayed generic approvals; Ohio rejects drug-price measure; Aetna CEO wants to improve in-person pharmacy experience

Five things for pharma marketers to know: Monday, November 6, 2017

Five things for pharma marketers to know: Monday, November 6, 2017

By

Valeant sells Addyi back to Sprout; some advertisers halt business with Outcome Health; Amgen cuts R&D jobs

Five things for pharma marketers to know: Friday, November 3, 2017

Five things for pharma marketers to know: Friday, November 3, 2017

By

Experimental Gilead and GSK HIV drugs are expected to compete; GSK R&D head resigns; Valeant subsidiary scores eye-drug approval

Five things for pharma marketers to know: Monday, October 30, 2017

Five things for pharma marketers to know: Monday, October 30, 2017

By

Novartis to acquire French biotech in bid to develop new cancer therapies; FDA hires former Mylan exec as comms adviser; health system sees drop in opioid scripts

Five things for pharma marketers to know: Friday, October 27, 2017

Five things for pharma marketers to know: Friday, October 27, 2017

By

CVS Health reportedly in talks to acquire Aetna; Amazon acquires wholesale pharmacy licenses; Merck says June cyberattack disrupted global operations

Five things for pharma marketers to know: Tuesday, October 24, 2017

Five things for pharma marketers to know: Tuesday, October 24, 2017

By

FDA approves Alexion's Soliris for another rare disease; Sun Pharma debuts companion mobile app for acne drug; Hurricane halts manufacturing in Puerto Rico

Five things for pharma marketers to know: Monday, October 16, 2017

Five things for pharma marketers to know: Monday, October 16, 2017

By

FDA briefing document affirms diabetes drug's efficacy; J&J debuts new tools to improve adherence; AZ says cancer drug data was falsified

Five things for pharma marketers to know: Friday, October 13, 2017

Five things for pharma marketers to know: Friday, October 13, 2017

By

Outcome Health reportedly misled advertisers; FDA committee recommends gene therapy; Avanir drug is highly prescribed by docs paid by company

Five things for pharma marketers to know: Wednesday, October 4, 2017

Five things for pharma marketers to know: Wednesday, October 4, 2017

By

The FDA approves Mylan's Copaxone generic; 3 out of every 1,000 Americans face $50,000 in drug costs; some ACA premiums may rise by 50%

Five things for pharma marketers to know: Tuesday, October 3, 2017

Five things for pharma marketers to know: Tuesday, October 3, 2017

By

The FDA wants to improve the generic drug approval process; Allergan CEO responds to criticism of patent deal; breast cancer death rate dropped 40%

Five things for pharma marketers to know: Friday, September 22, 2017

Five things for pharma marketers to know: Friday, September 22, 2017

By

Express Scripts' Miller says new models needed to pay for CAR-T; FDA warns about Intercept drug deaths; CVS puts limits on opioid scripts

Five things for pharma marketers to know: Wednesday, September 20, 2017

Five things for pharma marketers to know: Wednesday, September 20, 2017

By

Pfizer sues J&J over Remicade contracts; drugmakers trim sales forces for rare-disease drugs; Roche's oncology business under siege from biosimilars

Five things for pharma marketers to know: Thursday, September 14, 2017

Five things for pharma marketers to know: Thursday, September 14, 2017

By

One-third of clinical trials are never publicly registered; ICER revises PCSK9 cost-effectiveness analysis; flu shot linked to miscarriages

Five things for pharma marketers to know: Wednesday, September 13, 2017

Five things for pharma marketers to know: Wednesday, September 13, 2017

By

FDA closes pediatric study loophole; little evidence outcomes-based contracts are working; PBMs lobby against transparency efforts

Five things for pharma marketers to know: Tuesday, September 12, 2017

Five things for pharma marketers to know: Tuesday, September 12, 2017

By

Alexion to cut 600 jobs; Sage Therapeutics' experimental seizure drug fails to meet expectations; Apple is interested in medical and health activity

Five things for pharma marketers to know: Monday, September 11, 2017

Five things for pharma marketers to know: Monday, September 11, 2017

By

Teva names new CEO; Allergan transfers Restasis patent to skirt competition; Google invests in oncology

Five things for pharma marketers to know: Friday, September 8, 2017

Five things for pharma marketers to know: Friday, September 8, 2017

By

Pfizer receives warning letter over EpiPen manufacturing; Opdivo kidney-cancer trial shows improved survival rates; cancer patients who discuss costs with physicians pay less

Five things for pharma marketers to know: Thursday, September 7, 2017

Five things for pharma marketers to know: Thursday, September 7, 2017

By

The FDA halts IO-combo trial for Opdivo; Lilly slashes 3,500 jobs; new asthma drug could treat wide range of patients

Five things for pharma marketers to know: Wednesday, September 6, 2017

Five things for pharma marketers to know: Wednesday, September 6, 2017

By

The FDA warns drugmaker over opioid promotion; Watson may not be living up to the hype; Merck acquires immuno-oncology biotech

Five things for pharma marketers to know: Monday, August 28, 2017

Five things for pharma marketers to know: Monday, August 28, 2017

By

Gilead to acquire Kite; the FDA issues fewest number of warning letters since 2008; the regulator approves BI's Humira biosimilar

Five things for pharma marketers to know: Tuesday, August 22, 2017

Five things for pharma marketers to know: Tuesday, August 22, 2017

By

Novartis launches MS study with Apple's ResearchKit; the FDA considering limiting risk info in drug ads; J&J loses baby powder lawsuit

Five things for pharma marketers to know: Friday, August 11, 2017

Five things for pharma marketers to know: Friday, August 11, 2017

By

Egalet slashes workforce in favor of opioid education; Novo's experimental obesity drug reports positive results; Trump declares opioid crisis a national emergency

Five things for pharma marketers to know: Thursday, August 3, 2017

Five things for pharma marketers to know: Thursday, August 3, 2017

By

FDA committee votes against J&J arthritis drug; scientists successfully edit genes; Shire mulls ADHD spin off

Five things for pharma marketers to know: Friday, July 14, 2017

Five things for pharma marketers to know: Friday, July 14, 2017

By

The FDA approves J&J psoriasis drug; PARP inhibitors are not cost-effective, ICER says; Verily releases mosquitoes to combat Zika

Five things for pharma marketers to know: Wednesday, July 5, 2017

Five things for pharma marketers to know: Wednesday, July 5, 2017

By

Amgen and Teva raise prices of leukemia drugs twice this year; Roche acquires diabetes app; docs use Snapchat to share patient scans